中原医刊
中原醫刊
중원의간
CENTRAL PLAINS MEDICAL JOURNAL
2008年
8期
17-19
,共3页
慢性肝病%医院感染%防治
慢性肝病%醫院感染%防治
만성간병%의원감염%방치
Chronic liver diseases%Hospital infection%Prevention and treatment
目的 分析调查慢性肝病医院内感染的原因并探讨预防措施.方法 对慢性肝病合并医院内感染111例的临床资料进行回顾性调查并进行临床分析.结果 慢性肝病院内感染率为19.8%,慢性重型肝炎居首位,其次是肝癌,失代偿期肝硬化居第三,慢性肝炎居第四,经统计学检验差异有统计学意义.提示肝功能损害越重,医院感染发生率越高.呼吸系统感染最常见,其次是腹腔感染,胃肠道第三.病原学革兰氏阴性杆菌和阳性球菌为主,真菌也占相当比例.合并医院感染的病死率高于非医院感染者.结论 有效防治医院感染对于提高慢性肝病的疗效有极其重要的作用.
目的 分析調查慢性肝病醫院內感染的原因併探討預防措施.方法 對慢性肝病閤併醫院內感染111例的臨床資料進行迴顧性調查併進行臨床分析.結果 慢性肝病院內感染率為19.8%,慢性重型肝炎居首位,其次是肝癌,失代償期肝硬化居第三,慢性肝炎居第四,經統計學檢驗差異有統計學意義.提示肝功能損害越重,醫院感染髮生率越高.呼吸繫統感染最常見,其次是腹腔感染,胃腸道第三.病原學革蘭氏陰性桿菌和暘性毬菌為主,真菌也佔相噹比例.閤併醫院感染的病死率高于非醫院感染者.結論 有效防治醫院感染對于提高慢性肝病的療效有極其重要的作用.
목적 분석조사만성간병의원내감염적원인병탐토예방조시.방법 대만성간병합병의원내감염111례적림상자료진행회고성조사병진행림상분석.결과 만성간병원내감염솔위19.8%,만성중형간염거수위,기차시간암,실대상기간경화거제삼,만성간염거제사,경통계학검험차이유통계학의의.제시간공능손해월중,의원감염발생솔월고.호흡계통감염최상견,기차시복강감염,위장도제삼.병원학혁란씨음성간균화양성구균위주,진균야점상당비례.합병의원감염적병사솔고우비의원감염자.결론 유효방치의원감염대우제고만성간병적료효유겁기중요적작용.
Objective To investigate the reasons of hospital infection in patients with chronic liver diseases and probe into the preventive measures. Methods Clinical data of 111 hospital infection patients with chron-ic liver diseases were analyzed by retrospective analysis. Results The rate of hospital infection with chronic liver diseases was 19.8%. The first was chronic severe hepatitis;second was hepatocarcinoma;the next was de-compensated cirrhosis and chronic hepatitis was last. All of the above results were significant in statistics. It suggested that the higher hospital infection rate associated with degree of liver function damage. Respiratory tract infection was the highest and abdominal infection was the secondary; the third was gastrointestinal tract.The dominant pathogens were Gram - negative bacterium and Gram - positive cocci. Moreover, fungi had a considerable proportion. The mortality rate combined with hospital infection was higher than the non -infec-tions. Conclusion The prevention and treatment of hospital infection have important meanings for the im-provement of prognosis and increasing therapeutic effect on chronic liver diseases.